Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM5A | P29375 | 12/20 | 0.53 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.41 |
| ▸ | PLAT | P00750 | 2/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | KDM4D | Q6B0I6 | 1/20 | 0.39 |
| ▸ | PDE3B | Q13370 | 1/20 | 0.36 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.36 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.34 |
| ▸ | HPGD | P15428 | 1/20 | 0.34 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | HTT | P42858 | 1/20 | 0.33 |
| ▸ | RECQL | P46063 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16047129 | 0.91 | KDM5A (0.50) | KDM5AKDM4CPLATKDM4EALDH1A1 | |
| SCHEMBL16048043 | 0.91 | KDM5A (0.50) | KDM5AKDM4CPLATKDM4EALDH1A1 | |
| SCHEMBL16047075 | 0.90 | KDM5A (0.49) | KDM5AKDM4CPLATKDM4EALDH1A1 | |
| SCHEMBL16046459 | 0.89 | KDM5A (0.48) | KDM5AKDM4CPLATKDM4EALDH1A1 | |
| SCHEMBL16046985 | 0.87 | KDM5A (0.47) | KDM5AKDM4CPLATKDM4EALDH1A1 | |
| SCHEMBL16046861 | 0.86 | KDM5A (0.46) | KDM5AKDM4CPLATKDM4EALDH1A1 | |
| SCHEMBL16046987 | 0.86 | KDM5A (0.56) | KDM5AKDM4CPLATKDM4EALDH1A1 | |
| SCHEMBL16077832 | 0.85 | KDM5A (0.46) | KDM5AKDM4CPLATKDM4EALDH1A1 | |
| SCHEMBL16046157 | 0.85 | KDM5A (0.46) | KDM5AKDM4CPLATKDM4EALDH1A1 | |
| SCHEMBL16050639 | 0.85 | KDM5A (0.52) | KDM5AKDM4CPLATKDM4EALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160303095-A1 | METHODS OF TREATING HEPATITIS B VIRUS | GILEAD SCIENCES, INC. | 2016-10-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160303095-A1 | METHODS OF TREATING HEPATITIS B VIRUS | KDM1B, KDM5B, KDM5A | KDM5A 3/4885KDM4C 23/4885PLAT 3247/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.